DNA X, Inc.
For the period ended Dec 31, 2025. Filed Apr 15, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Apr 15, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized**.**
| DNA X, Inc. | ||
| Date: April 14, 2026 | By: | /s/ Clay Crolius |
|---|---|---|
| Clay Crolius | ||
| Chief Financial Officer (Principal Financial and Accounting Officer) | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Mike Mulica | Acting Chief Executive Officer and Chairman of the Board | April 14, 2026 |
| Mike Mulica | (Principal Executive Officer) | |
| /s/ Clay Crolius | Chief Financial Officer | April 14, 2026 |
| Clay Crolius | (Principal Financial and Accounting Officer) | |
| /s/ Scott Walker | Director | April 14, 2026 |
| Scott Walker | ||
| /s/ George Thangadurai | Director | April 14, 2026 |
| George Thangadurai | ||
| /s/ Jack Steenstra | Director | April 14, 2026 |
| Jack Steenstra | ||
| /s/ James Cassano | Director | April 14, 2026 |
| James Cassano | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.